A step towards making AI accessible to all researchers: an interview with John Overington
Last week, Medicines Discovery Catapult (Cheshire, UK) and Chief.AI announced they will be working together to make artificial intelligence more accessible for all researchers. We spoke with John Overington (Medicines Discovery Catapult) to learn more about the use of artificial intelligence in drug discovery.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>